AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00513279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 matching placebo tablets
Description: GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
Study NCT04914455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography and transhepatic inferior vena cava assessment using ultrasound.
Description: For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;
Study NCT03651882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
Study NCT00544466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 day -2 prior to transplant
Study NCT00544466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Cells infused on Day 0 of transplant regimen
Study NCT00544466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
Study NCT03424044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Dual Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
Study NCT03424044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Single Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
Study NCT03424044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
Study NCT03424044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XeriSol glucagon
Description: XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
Study NCT00674687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2-weeks placebo then gabapentin
Description: Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
Study NCT00674687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-week placebo then gabapentin
Description: Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
Study NCT03651882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin is given 0.1mg intravenously as a bolus after delivery.
Study NCT02059538 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)
Study NCT01777009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Total Knee Replacement Surgery
Description: Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
Study NCT01777009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Total Knee Replacement Surgery
Description: Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
Study NCT02398487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cigalike with nicotine
Description: cigalike 24 mg nicotine or 16 mg nicotine
Study NCT02398487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Vaporizer with nicotine
Description: Personal Vaporizer 16 mg nicotine or 9 mg nicotine
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
Study NCT02576275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
Study NCT02632071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACY-1215
Description: An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Study NCT02632071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Study NCT05021341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
Study NCT05021341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroberberine 200
Description: For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
Study NCT05021341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroberberine 100
Description: For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
Study NCT05021341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
Study NCT01231438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Description: 800mg t.i.d. over 2 weeks
Study NCT01231438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etalpha
Description: 0.25ug o.d. for 2 weeks
Study NCT03821636 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass
Description: Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
Study NCT03821636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long alimentary limb Roux-en-Y gastric bypass
Description: Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
Study NCT04664998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic test for NG/CT
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.
Study NCT04664998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.
Study NCT02612142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: endurance-training or stretching (sham exercise)
Study NCT02612142 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: physical exercise
Description: endurance-training or stretching (sham exercise)
Study NCT01746706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET amyloid tracer (Florbetapir F18 AV45 F18
Study NCT01790672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Vodka Absolut
Study NCT01790672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Lemon-flavored water
Study NCT01790672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcoholized wine
Description: Wine 13º or wine 8º
Study NCT01790672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: De-alcoholized wine
Description: Wine 0º
Study NCT05688540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e book
Description: e book
Study NCT05688540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional education booklet
Description: traditional education booklet
Study NCT02280096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-aminopyridine
Description: Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
Study NCT02280096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm will include Microcrystalline Cellulose placebo
Study NCT03169114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin Injection
Description: Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
Study NCT03169114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendicectomy
Description: Patients allocated to Surgery Management Strategy will undergo appendicectomy
Study NCT00581126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor IX Coagulation
Description: Benefix IV each 12 hours for 2 a 5 days
Study NCT00802594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB289
Description: A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
Study NCT03936426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64 SARTATE and Cu-67 SARTATE
Description: Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
Study NCT02005263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingography
Description: Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
Study NCT04400682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIRA 200 MG Film Tablet
Description: FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
Study NCT04400682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study NCT03247192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein-placebo
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
Study NCT03247192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo-whey protein
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
Study NCT03247192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-placebo
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
Study NCT02445976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel: given orally once daily in 28-day cycles
Description: Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study NCT00570700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 150mg (3 pills) orally daily for as long as the drug benefits
Study NCT03131128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: 1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food.
Study NCT03131128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: 1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia.
Study NCT01094626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
Study NCT03547102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry concentrate
Study NCT03547102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo concentrate
Study NCT03257410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Description: Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Study NCT02733146 — intervention group
Intervention type: OTHER
Intervention: cardiac arrest